NCT05492370 is a NA clinical trial of EpiCor in Signs and Symptoms, Respiratory, sponsored by Cargill.

Who is sponsoring NCT05492370?

NCT05492370 is sponsored by Cargill.

What drugs are being tested in NCT05492370?

Interventions in NCT05492370: EpiCor, Placebo.

What condition does NCT05492370 study?

NCT05492370 studies Signs and Symptoms, Respiratory.

Is NCT05492370 still recruiting?

NCT05492370 is currently completed. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT05492370

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of a Yeast Fermentate (EpiCor) Supplement on Cold or Flu Symptoms in Healthy Children

Completed NA Last updated 18 November 2023

What this trial tests

NA trial testing EpiCor in Signs and Symptoms, Respiratory in 256 participants. Completed in 19 July 2023.

Timeline

7 September 2022

Primary endpoint
18 April 2023

19 July 2023

Quick facts

Lead sponsor	Cargill
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	256
Start date	7 September 2022
Primary completion	18 April 2023
Estimated completion	19 July 2023
Sites	1 location across Canada

Drugs / interventions tested

EpiCor
Placebo

Conditions studied

Signs and Symptoms, Respiratory — all drugs for Signs and Symptoms, Respiratory →

Sponsor

Cargill — full company profile →

Who can join

Adults 4 to 12, any sex, with Signs and Symptoms, Respiratory. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a double-blind, randomized, placebo-controlled study. The purpose of the clinical study is to determine the difference between 84 days of once daily oral EpiCor supplementation compared to placebo on the incidence of cold or flu symptoms among children aged 4-12 years who are attending school or daycare.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of EpiCor

Trials testing the same drug.

NCT03051399 — Clinical Evaluation of the Effects of EpiCor on Digestive Comfort · NA · completed

Other Cargill trials

Trials by the same sponsor.

NCT05819424 — EpiCor Clinical Study on Rapid Immune Modulating Effects · NA · completed
NCT05264636 — The Impact of Steviol Glycosides on Human Gut Microflora Profile and Function · NA · completed
NCT04093206 — Compare Effects of EpiCor and Vitamin C to Vitamin C Alone on the Common Cold or Influenza in Healthy Children · NA · completed
NCT03239288 — A Randomized, Controlled, Crossover Study to Assess the Glucose and Insulin Excursions of a Test Fiber · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05492370 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cargill
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05492370.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing